1. Jacobson SH, Hansson S, Jakobsson B. Vesicoureteric reflux: occurrence and longterm risks. Acta Paediatr Suppl. 1999; 88:22–30.
Article
2. Elmore JM, Kirsch AJ, Heiss EA, Gilchrist A, Scherz HC. Incidence of urinary tract infections in children after successful ureteral reimplantation versus endoscopic dextranomer/hyaluronic acid implantation. J Urol. 2008; 179:2364–7.
Article
3. Smellie JM, Barratt TM, Chantler C, Gordon I, Prescod NP, Ransley PG, et al. Medical versus surgical treatment in children with severe bilateral vesicoureteric reflux and bilateral nephropathy: a randomised trial. Lancet. 2001; 357:1329–33.
Article
4. Hoberman A, Charron M, Hickey RW, Baskin M, Kearney DH, Wald ER. Imaging studies after a first febrile urinary tract infection in young children. N Engl J Med. 2003; 348:195–202.
Article
5. Wadie GM, Moriarty KP. The impact of vesicoureteral reflux treatment on the incidence of urinary tract infection. Pediatr Nephrol. 2012; 27:529–38.
Article
6. Elder JS, Diaz M, Caldamone AA, Cendron M, Greenfield S, Hurwitz R, et al. Endoscopic therapy for vesicoureteral reflux: a metaanalysis. I. Reflux resolution and urinary tract infection. J Urol. 2006; 175:716–22.
Article
7. Baek M, Kim KD. Current surgical management of vesicoureteral reflux. Korean J Urol. 2013; 54:732–7.
Article
8. Traxel E, DeFoor W, Reddy P, Sheldon C, Minevich E. Risk factors for urinary tract infection after dextranomer/hyaluronic acid endoscopic injection. J Urol. 2009; 182(4 Suppl):1708–12.
Article
9. Chi A, Gupta A, Snodgrass W. Urinary tract infection following successful dextranomer/hyaluronic acid injection for vesicoureteral reflux. J Urol. 2008; 179:1966–9.
Article
10. Biočić M, Todorić J, Budimir D, Cvitković Roić A, Pogorelić Z, Jurić I; I, et al. Endoscopic treatment of vesicoureteral reflux in children with subureteral dextranomer/hyaluronic acid injection: a single-centre, 7-year experience. Can J Surg. 2012; 55:301–6.
Article
11. Chung PH, Lan LC, Wong KK, Tam PK. Deflux injection for the treatment of vesicoureteric reflux in children–a single centre's experience. Asian J Surg. 2009; 32:163–6.
Article
12. O'Donnell B, Puri P. Treatment of vesicoureteric reflux by endoscopic injection of Teflon. Br Med J. 1984; 289:7–9.
13. Hunziker M, Mohanan N, D'Asta F, Puri P. Incidence of febrile urinary tract infections in children after successful endoscopic treatment of vesicoureteral reflux: a longterm followup. J Pediatr. 2012; 160:1015–20.
Article
14. Fenton JJ, Mirza SK, Lahad A, Stern BD, Deyo RA. Variation in reported safety of lumbar interbody fusion: influence of industrial sponsorship and other study characteristics. Spine (Phila Pa 1976). 2007; 32:471–80.
15. Peters CA, Skoog SJ, Arant BS Jr, Copp HL, Elder JS, Hudson RG, et al. Summary of the aua guideline on management of primary vesicoureteral reflux in children. J Urol. 2010; 184:1134–44.
Article
16. Jodal U, Koskimies O, Hanson E, Löhr G, Olbing H, Smellie J, et al. Infection pattern in children with vesicoureteral reflux randomly allocated to operation or longterm antibacterial prophylaxis. The International Reflux Study in Children. J Urol. 1992; 148:1650–2.
17. Beetz R, Mannhardt W, Fisch M, Stein R, Thüroff JW. Longterm followup of 158 young adults surgically treated for vesicoureteral reflux in childhood: the ongoing risk of urinary tract infections. J Urol. 2002; 168:704–7. discussion 707.
Article
18. Läckgren G, Wåhlin N, Sköldenberg E, Stenberg A. Longterm followup of children treated with dextranomer/hyaluronic acid copolymer for vesicoureteral reflux. J Urol. 2001; 166:1887–92.
19. Chi A, Gupta A, Snodgrass W. Urinary tract infection following successful dextranomer/hyaluronic acid injection for vesicoureteral reflux. J Urol. 2008; 179:1966–9.
Article
20. Traxel E, DeFoor W, Reddy P, Sheldon C, Minevich E. Risk factors for urinary tract infection after dextranomer/hyaluronic acid endoscopic injection. J Urol. 2009; 182(4 Suppl):1708–12.
Article
21. Elmore JM, Kirsch AJ, Heiss EA, Gilchrist A, Scherz HC. Incidence of urinary tract infections in children after successful ureteral reimplantation versus endoscopic dextranomer/hyaluronic acid implantation. J Urol. 2008; 179:2364–7. discussion 2367-8.
Article
22. Wadie GM, Tirabassi MV, Courtney RA, Moriarty KP. The deflux procedure reduces the incidence of urinary tract infections in patients with vesicoureteral reflux. J Laparoendosc Adv Surg Tech A. 2007; 17:353–9.
Article
23. Puri P, Pirker M, Mohanan N, Dawrant M, Dass L, Colhoun E. Subureteral dextranomer/hyaluronic acid injection as first line treatment in the management of high grade vesicoureteral reflux. J Urol. 2006; 176:1856–9.
Article
24. Sedberry-Ross S, Rice DC, Pohl HG, Belman AB, Majd M, Rushton HG. Febrile urinary tract infections in children with an early negative voiding cystourethrogram after treatment of vesicoureteral reflux with dextranomer/hyaluronic acid. J Urol. 2008; 180(4 Suppl):1605–9. discussion 1610.
Article
25. Snodgrass W. Relationship of voiding dysfunction to urinary tract infection and vesicoureteral reflux in children. Urology. 1991; 38:341–4.